Tumour mutational burden: primary versus metastatic tissue creates systematic bias

Tumour mutational burden (TMB) has emerged as a reproducible biomarker to predict immunotherapy response across multiple cancer types. However, a key aspect of TMB measurement that is often overlooked is the source of tissue sample used, which creates a potential for systematic bias. The predominant...

Descripción completa

Detalles Bibliográficos
Autores principales: Schnidrig, Desiree, Turajlic, Samra, Litchfield, Kevin
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Elsevier 2019
Materias:
Technology Explained
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9216665/
https://www.ncbi.nlm.nih.gov/pubmed/35755001
http://dx.doi.org/10.1016/j.iotech.2019.11.003

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9216665/
https://www.ncbi.nlm.nih.gov/pubmed/35755001
http://dx.doi.org/10.1016/j.iotech.2019.11.003

Ejemplares similares